Literature DB >> 9024069

Effusion cytology after extrapleural pneumonectomy for treatment of malignant mesothelioma.

A A Renshaw1, D Nappi, S Swanson, D J Sugarbaker.   

Abstract

Extrapleural pneumonectomy to treat malignant mesothelioma may offer a significant survival advantage for selected patients. The role of effusion cytology in these patients has not been previously examined. To evaluate this, cytology, pathology, and medical records of 26 cases in 21 patients who underwent extrapleural pneumonectomy because of malignant mesothelioma were reviewed. Positive cytologic results were noted on average 13 months later than negative results. Recurrence was most common in the peritoneum, followed by the ipsilateral thorax and contralateral thorax. Five of 11 true-negative results were secondary to infection; cytologic analysis revealed neutrophils in each case. Four of 5 false-negative cases were from the ipsilateral thorax, and no mesothelial cells were found. When these 4 cases are excluded, the sensitivity of cytologic examination in this setting was 91%, and specificity was 100%. Effusion cytology in patients after extrapleural pneumonectomy is an effective means of diagnosing recurrent malignant mesothelioma.

Entities:  

Mesh:

Year:  1997        PMID: 9024069     DOI: 10.1093/ajcp/107.2.206

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Cytological Diagnostic Procedures in Malignant Mesothelioma.

Authors:  Christian Biancosino; Lea Isabell Shari van der Linde; Guido Sauter; Florian Stellmacher; Marcus Krüger; Lutz Welker
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.

Authors:  Sanjeevan Muruganandan; Helman Alfonso; Peter Franklin; Keith Shilkin; Amanda Segal; Nola Olsen; Alison Reid; Nick de Klerk; Aw Bill Musk; Fraser Brims
Journal:  Br J Cancer       Date:  2017-02-14       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.